

U.S. Patent Application No. 10/537,001
Supplemental Amendment dated February 5, 2007
Reply to Office Action of August 24, 2006

RECEIVED
CENTRAL FAX CENTER
FEB 05 2007

LISTING OF CLAIMS:

- 1-25. (Canceled)
26. (Previously presented) An agent for inhibiting metastasis of colorectal cancer, wherein the agent inhibits the expression of the Asef (APC-stimulated guanine nucleotide exchange factor) gene, by the RNA interference on the expression of the gene, or by antisense inhibition on the expression of the gene.
27. (Withdrawn) The agent of claim 26, wherein the agent inhibits the binding of Asef (APC-stimulated guanine nucleotide exchange factor) to the gene product of APC (Adenomatous Polyposis Coli).
28. (Withdrawn) The agent of claim 26, wherein the agent inhibits the guanine nucleotide exchange factor activity of Asef (APC-stimulated guanine nucleotide exchange factor).
29. (Withdrawn) A method for inhibiting metastasis of colorectal cancer, wherein the method comprises inhibiting the function of Asef (APC-stimulated guanine nucleotide exchange factor) and/or inhibits the expression of the Asef gene.
30. (Withdrawn) The method of claim 29, wherein the method comprises inhibiting the expression of the Asef (APC-stimulated guanine nucleotide exchange factor) gene.
31. (Withdrawn) The method of claim 29, wherein the method comprises inhibiting the binding of Asef (APC-stimulated guanine nucleotide exchange factor) to the gene product of APC (Adenomatous Polyposis Coli).
32. (Withdrawn) The method of claim 29, wherein the method comprises inhibiting the guanine nucleotide exchange factor activity of Asef (APC-stimulated guanine nucleotide exchange factor).
33. (Previously presented) An agent for inhibiting metastasis of colorectal cancer, wherein

U.S. Patent Application No. 10/537,001
Supplemental Amendment dated February 5, 2007
Reply to Office Action of August 24, 2006

the agent inhibits the expression of the Asef (APC-stimulated guanine nucleotide exchange factor) gene by the RNA interference on the expression of the gene.

34. (Previously presented) The agent of claim 33, wherein the agent comprises an oligonucleotide that exhibits an RNA interference effect on the expression of the Asef (APC-stimulated guanine nucleotide exchange factor) gene.

35. (Withdrawn) A method for inhibiting metastasis of colorectal cancer, wherein the method comprises inhibiting the expression of the Asef (APC-stimulated guanine nucleotide exchange factor) gene or APC (Adenomatous Polyposis Coli) gene by the RNA interference on the expression of the gene.

36. (Withdrawn) The method of claim 35, wherein the method comprises using an oligonucleotide that exhibits an RNA interference effect on the expression of the Asef (APC-stimulated guanine nucleotide exchange factor) gene or APC (Adenomatous Polyposis Coli) gene.

37. (Previously presented) An oligonucleotide consisting of the nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing.

38. (Previously presented) A pharmaceutical composition comprising the oligonucleotide of claim 37, and a pharmaceutical carrier.

39. (Withdrawn) An agent for inhibiting APC (Adenomatous Polyposis Coli), wherein the agent comprises an oligonucleotide of claim 37, having the nucleotide sequence set forth in SEQ ID NO: 2 or 4 in the sequence listing.

40. (Withdrawn) A method for inhibiting Asef (APC-stimulated guanine nucleotide exchange factor), wherein the method comprises using an oligonucleotide of claim 37, having the nucleotide sequence set forth in SEQ ID NO: 1 or 3 in the sequence listing.

U.S. Patent Application No. 10/537,001
Supplemental Amendment dated February 5, 2007
Reply to Office Action of August 24, 2006

41. (Withdrawn) A method for inhibiting APC (Adenomatous Polyposis Coli), wherein the method comprises using an oligonucleotide of claim 37, having the nucleotide sequence set forth in SEQ ID NO: 2 or 4 in the sequence listing.
42. (Previously presented) The agent of claim 34, wherein the oligonucleotide consists of the nucleotide sequence set forth in any one of SEQ ID NOS: 1 to 4 in the sequence listing.
43. (Canceled)
44. (Withdrawn) The method of claim 36, wherein the oligonucleotide has the nucleotide sequence set forth in any one of SEQ ID NOS: 1 to 4 in the sequence listing.
45. (Withdrawn) A method for inhibiting metastasis of colorectal cancer, wherein the method comprises using the agent of claim 38.
46. (Withdrawn) A method for preventing and/or treating colorectal cancer, wherein the method comprises using the agent of claim 26.
47. (Withdrawn) A method for preventing and/or treating colorectal cancer, wherein the method comprises using the agent of claim 38.
48. (Withdrawn) An agent for inhibiting metastasis of colorectal cancer, wherein the agent comprises the agent of claim 39.
49. (Withdrawn) A method for inhibiting metastasis of colorectal cancer, wherein the method comprises using the agent of claim 39.
50. (Withdrawn) A method for preventing and/or treating colorectal cancer, wherein the method comprises using the agent of claim 33.
51. (Withdrawn) A method for preventing and/or treating colorectal cancer, wherein the method comprises using the agent of claim 39.